{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T02:24:53Z","timestamp":1767666293068,"version":"build-2065373602"},"reference-count":11,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.4158\/ep.15.3.229","type":"journal-article","created":{"date-parts":[[2013,4,5]],"date-time":"2013-04-05T22:32:04Z","timestamp":1365201124000},"page":"229-233","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Minimal Reduction in Insulin Dosage with Pramlintide Therapy When Pretreatment Near-Normal Glycemia is Established and Square-Wave Meal Bolus is Used"],"prefix":"10.1016","volume":"15","author":[{"given":"Allen B.","family":"King","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP.15.3.229_bb0005","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0026-0495(99)90232-9","article-title":"The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus","volume":"48","author":"Nyholm","year":"1999","journal-title":"Metabolism."},{"key":"10.4158\/EP.15.3.229_bb0010","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/j.1464-5491.2004.01319.x","article-title":"Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year, randomized controlled trial","volume":"21","author":"Ratner","year":"2004","journal-title":"Diabet Med."},{"key":"10.4158\/EP.15.3.229_bb0015","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.2337\/diacare.26.11.3074","article-title":"Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study","volume":"26","author":"Weyer","year":"2003","journal-title":"Diabetes Care."},{"key":"10.4158\/EP.15.3.229_bb0020","doi-asserted-by":"crossref","first-page":"724","DOI":"10.2337\/diacare.25.4.724","article-title":"A randomized study and open-label extension evaluating the longterm efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes","volume":"25","author":"Whitehouse","year":"2002","journal-title":"Diabetes Care."},{"key":"10.4158\/EP.15.3.229_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/diacare.26.1.1","article-title":"Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps","volume":"26","author":"Levetan","year":"2003","journal-title":"Diabetes Care."},{"key":"10.4158\/EP.15.3.229_bb0030","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.2337\/dc06-0042","article-title":"A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes","volume":"29","author":"Edelman","year":"2006","journal-title":"Diabetes Care."},{"key":"10.4158\/EP.15.3.229_bb0035","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/BF00400683","article-title":"Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM","volume":"39","author":"Kolterman","year":"1996","journal-title":"Diabetologia."},{"key":"10.4158\/EP.15.3.229_bb0040","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/193229680700100107","article-title":"A prospective evaluation of insulin dosing recommendations in patients with type 1 diabetes at near normal glucose control: bolus dosing","volume":"1","author":"King","year":"2007","journal-title":"J Diabetes Sci Technol."},{"key":"10.4158\/EP.15.3.229_bb0045","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1177\/193229680700100106","article-title":"A prospective evaluation of insulin dosing recommendations in patients with type 1 diabetes at near normal glucose control: basal dosing","volume":"1","author":"King","year":"2007","journal-title":"J Diabetes Sci Technol."},{"key":"10.4158\/EP.15.3.229_bb0050","series-title":"Therapy for Diabetes Mellitus and Related Disorders","first-page":"224","article-title":"Insulin pump therapy","author":"Bode","year":"2004"},{"key":"10.4158\/EP.15.3.229_bb0055","first-page":"237","article-title":"Statistically based CSII parameters: correction factor, CF (1700 rule), carbohydrate-to-insulin ratio, CIR (2.8 rule), and basal-to-total ratio","volume":"5","author":"Davidson","year":"2003","journal-title":"Diabetes Technol Ther"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20407669?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20407669?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/235210W120G78243.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:49:11Z","timestamp":1761515351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20407669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["S1530891X20407669"],"URL":"https:\/\/doi.org\/10.4158\/ep.15.3.229","relation":{},"ISSN":["1530-891X"],"issn-type":[{"type":"print","value":"1530-891X"}],"subject":[],"published":{"date-parts":[[2009,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Minimal Reduction in Insulin Dosage with Pramlintide Therapy When Pretreatment Near-Normal Glycemia is Established and Square-Wave Meal Bolus is Used","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP.15.3.229","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}